Dr. Bogdana Schmidt

And I think as a surgeon, we all want intravascular treatments for localized disease, one, because that's something we're comfortable with. But two, I think it more comes to the fact that we're comfortable managing those side effects, right? We know what to expect. We know kind of the worst case scenario for the patient.

And I think as a surgeon, we all want intravascular treatments for localized disease, one, because that's something we're comfortable with. But two, I think it more comes to the fact that we're comfortable managing those side effects, right? We know what to expect. We know kind of the worst case scenario for the patient.

And I think as a surgeon, we all want intravascular treatments for localized disease, one, because that's something we're comfortable with. But two, I think it more comes to the fact that we're comfortable managing those side effects, right? We know what to expect. We know kind of the worst case scenario for the patient.

And we know it's not going to necessarily be a hospital stay or, you know, stress dose steroids or anything kind of adverse immune. So as we develop more of these interesting mechanisms or delivery mechanisms, I think that we'll be able to offer our patients some new, better treatments than what we've had for them since the 70s.

And we know it's not going to necessarily be a hospital stay or, you know, stress dose steroids or anything kind of adverse immune. So as we develop more of these interesting mechanisms or delivery mechanisms, I think that we'll be able to offer our patients some new, better treatments than what we've had for them since the 70s.

And we know it's not going to necessarily be a hospital stay or, you know, stress dose steroids or anything kind of adverse immune. So as we develop more of these interesting mechanisms or delivery mechanisms, I think that we'll be able to offer our patients some new, better treatments than what we've had for them since the 70s.

55%, which is, you're absolutely right. The durability is where it counts, right? That 83% number, that response at any point, that's great. We're all excited. But if at three months it looks great and at six months it's all back, then that wouldn't really help the patient. That just cost him a lot of money.

55%, which is, you're absolutely right. The durability is where it counts, right? That 83% number, that response at any point, that's great. We're all excited. But if at three months it looks great and at six months it's all back, then that wouldn't really help the patient. That just cost him a lot of money.

55%, which is, you're absolutely right. The durability is where it counts, right? That 83% number, that response at any point, that's great. We're all excited. But if at three months it looks great and at six months it's all back, then that wouldn't really help the patient. That just cost him a lot of money.

And you're right. We may see different data in longer-term follow-up. And once the noise, kind of the numbers of the patients that drop off, we might get a clearer signal with that. These are all still in the abstract phase. So we might learn more in that. But I still think it's exciting and promising. And so to get to exciting and promising, we've talked about periop immunotherapy.

And you're right. We may see different data in longer-term follow-up. And once the noise, kind of the numbers of the patients that drop off, we might get a clearer signal with that. These are all still in the abstract phase. So we might learn more in that. But I still think it's exciting and promising. And so to get to exciting and promising, we've talked about periop immunotherapy.

And you're right. We may see different data in longer-term follow-up. And once the noise, kind of the numbers of the patients that drop off, we might get a clearer signal with that. These are all still in the abstract phase. So we might learn more in that. But I still think it's exciting and promising. And so to get to exciting and promising, we've talked about periop immunotherapy.

We've talked about biomarkers. We've talked about better intravesical intensification treatments. You've certainly mentioned, obviously, the big lofty goal of trying to decrease the number of bladders that we remove and making sure our patients live longer that way. What do you think is going to happen in the next six months to a year?

We've talked about biomarkers. We've talked about better intravesical intensification treatments. You've certainly mentioned, obviously, the big lofty goal of trying to decrease the number of bladders that we remove and making sure our patients live longer that way. What do you think is going to happen in the next six months to a year?

We've talked about biomarkers. We've talked about better intravesical intensification treatments. You've certainly mentioned, obviously, the big lofty goal of trying to decrease the number of bladders that we remove and making sure our patients live longer that way. What do you think is going to happen in the next six months to a year?

What do you think we're going to be talking about at the next ESMO or at the next GU-ASCO? Kind of what's in the pipeline that you're looking to hear about?

What do you think we're going to be talking about at the next ESMO or at the next GU-ASCO? Kind of what's in the pipeline that you're looking to hear about?

What do you think we're going to be talking about at the next ESMO or at the next GU-ASCO? Kind of what's in the pipeline that you're looking to hear about?

Absolutely. Well, I think it's definitely an exciting time to be in the bladder cancer space, which is a wonderful thing for our patients and certainly an interesting thing for us. A lot to keep up with, but it's definitely promising. Well, I want to thank you for a wonderful discussion. This was so great.

Absolutely. Well, I think it's definitely an exciting time to be in the bladder cancer space, which is a wonderful thing for our patients and certainly an interesting thing for us. A lot to keep up with, but it's definitely promising. Well, I want to thank you for a wonderful discussion. This was so great.